Please assess the completion status of the following clinical trial:

Trial Title: Treatment Simplification by Darunavir/Ritonavir 800/100 mg Once a Day Versus a Triple Combination Therapy With Darunavir/Ritonavir

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with documented HIV-1 infection~* Patients currently receiving HAART for at least 24 weeks~* Plasma viral load \< 50 copies/mL for at least 24 weeks prior to screening (two results must be documented)~* Patients taking the same antiretroviral combination for at least 8 weeks before screening~* Patients and physician's preference to change the current HAART regimen for reasons of simplification and/or toxicity~* CD4 \> 100/mm3 at the start of HAART and \> 200/mm3 at screening.~Exclusion Criteria:~* No history of virological failure defined as two consecutive plasma HIV-1 RNA \> 500 copies/mL while on previous or current antiretroviral therapy~* No history of any primary PI mutations as defined by the IAS-USA guidelines 2006~* No patients co-infected with hepatitis B~* No pregnant or breastfeeding women~* No active clinically significant disease or life threatening disease or findings during screening of medical history or physical examination that, in the investigator's opinion, would compromise the patient's safety or outcome of the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- darunavir monotherapy (Type: EXPERIMENTAL): darunavir (DRV, TMC114) 800 mg qd (2 x 400 mg tablet) monotherapy for 144 weeks
- darunavir + 2 NRTI (Type: EXPERIMENTAL): darunavir (DRV, TMC114) 800 mg qd (2 x 400 mg tablet) + 2 NRTI for 144 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).